More

    Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025



    [
    Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
    [og_img]
    https://www.investing.com/news/press-releases/sutro-biopharma-presents-data-from-doseoptimization-portion-of-refrimeo1-trial-in-patients-with-platinum-resistant-ovarian-cancer-at-sgo-2025-93CH-3930796


    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here

    spot_imgspot_img